Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 2
EGFR-Mutated NSCLC Disease Risk Stratification
Panelists discuss how disease-related factors like central nervous system (CNS) involvement or specific metastatic sites can guide treatment selection, favoring agents with CNS penetration or targeted efficacy. Mutational factors, such as TP53 comutations, may impact therapy response. Patient-related aspects, including age and comorbidities, influence tolerability and regimen choice.
Video content above is prompted by the following:
- In your expertise, which disease-related factors, such as CNS involvement or site of metastases, might suggest a preference for one treatment over the others?
- What about mutational factors—for example, a TP53 comutation? Additionally, how do patient-related factors such as age and comorbidities influence your choice?
Related Content:
